Literature DB >> 32300916

Messenger RNA-Based Vaccines Against Infectious Diseases.

Mohamad-Gabriel Alameh1, Drew Weissman2, Norbert Pardi1.   

Abstract

In vitro-transcribed, messenger RNA-based infectious disease vaccines have the potential to successfully address many of the weaknesses of traditional vaccine platforms, such as the lack of potency and/or durability of vaccine protection, time-consuming, and expensive manufacturing, and, in some cases, safety issues. This optimism is fueled by a great deal of impressive recent data demonstrating that mRNA vaccines have many of the attributes that are necessary for a viable new vaccine class for human use. This review briefly describes mRNA vaccine types, discusses the most relevant and recent publications on infectious disease mRNA vaccines, and highlights the hurdles that need to be overcome to bring this promising novel vaccine modality to the clinic.

Entities:  

Keywords:  Clinical trials; Infectious diseases; LNP; SAM; Vaccines; mRNA

Year:  2020        PMID: 32300916     DOI: 10.1007/82_2020_202

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  18 in total

Review 1.  Lymphadenopathy in the era of COVID-19 vaccination - an oncological dilemma in diagnostic imaging.

Authors:  Jakub Samkowski; Katarzyna Sklinda; Jerzy Michał Walecki
Journal:  Pol J Radiol       Date:  2022-06-06

2.  2021: an immunotherapy odyssey and the rise of nucleic acid nanotechnology.

Authors:  Martin Panigaj; Marina A Dobrovolskaia; Kirill A Afonin
Journal:  Nanomedicine (Lond)       Date:  2021-06-25       Impact factor: 6.096

Review 3.  Nanomaterial Delivery Systems for mRNA Vaccines.

Authors:  Michael D Buschmann; Manuel J Carrasco; Suman Alishetty; Mikell Paige; Mohamad Gabriel Alameh; Drew Weissman
Journal:  Vaccines (Basel)       Date:  2021-01-19

Review 4.  HIV mRNA Vaccines-Progress and Future Paths.

Authors:  Zekun Mu; Barton F Haynes; Derek W Cain
Journal:  Vaccines (Basel)       Date:  2021-02-07

5.  Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

Authors:  Gui-Ling Chen; Xiao-Feng Li; Xia-Hong Dai; Nan Li; Meng-Li Cheng; Zhen Huang; Jian Shen; Yu-Hua Ge; Zhen-Wei Shen; Yong-Qiang Deng; Shu-Yuan Yang; Hui Zhao; Na-Na Zhang; Yi-Fei Zhang; Ling Wei; Kai-Qi Wu; Meng-Fei Zhu; Cong-Gao Peng; Qi Jiang; Shou-Chun Cao; Yu-Hua Li; Dan-Hua Zhao; Xiao-Hong Wu; Ling Ni; Hua-Hao Shen; Chen Dong; Bo Ying; Guo-Ping Sheng; Cheng-Feng Qin; Hai-Nv Gao; Lan-Juan Li
Journal:  Lancet Microbe       Date:  2022-01-24

Review 6.  Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2.

Authors:  Javier T Granados-Riveron; Guillermo Aquino-Jarquin
Journal:  Biomed Pharmacother       Date:  2021-07-23       Impact factor: 6.529

7.  A Thermostable mRNA Vaccine against COVID-19.

Authors:  Na-Na Zhang; Xiao-Feng Li; Yong-Qiang Deng; Hui Zhao; Yi-Jiao Huang; Guan Yang; Wei-Jin Huang; Peng Gao; Chao Zhou; Rong-Rong Zhang; Yan Guo; Shi-Hui Sun; Hang Fan; Shu-Long Zu; Qi Chen; Qi He; Tian-Shu Cao; Xing-Yao Huang; Hong-Ying Qiu; Jian-Hui Nie; Yuhang Jiang; Hua-Yuan Yan; Qing Ye; Xia Zhong; Xia-Lin Xue; Zhen-Yu Zha; Dongsheng Zhou; Xiao Yang; You-Chun Wang; Bo Ying; Cheng-Feng Qin
Journal:  Cell       Date:  2020-07-23       Impact factor: 41.582

8.  D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.

Authors:  Drew Weissman; Mohamad-Gabriel Alameh; Thushan de Silva; Paul Collini; Hailey Hornsby; Rebecca Brown; Celia C LaBranche; Robert J Edwards; Laura Sutherland; Sampa Santra; Katayoun Mansouri; Sophie Gobeil; Charlene McDanal; Norbert Pardi; Nick Hengartner; Paulo J C Lin; Ying Tam; Pamela A Shaw; Mark G Lewis; Carsten Boesler; Uğur Şahin; Priyamvada Acharya; Barton F Haynes; Bette Korber; David C Montefiori
Journal:  Cell Host Microbe       Date:  2020-12-01       Impact factor: 31.316

9.  A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.

Authors:  Dorottya Laczkó; Michael J Hogan; Sushila A Toulmin; Philip Hicks; Katlyn Lederer; Brian T Gaudette; Diana Castaño; Fatima Amanat; Hiromi Muramatsu; Thomas H Oguin; Amrita Ojha; Lizhou Zhang; Zekun Mu; Robert Parks; Tomaz B Manzoni; Brianne Roper; Shirin Strohmeier; István Tombácz; Leslee Arwood; Raffael Nachbagauer; Katalin Karikó; Jack Greenhouse; Laurent Pessaint; Maciel Porto; Tammy Putman-Taylor; Amanda Strasbaugh; Tracey-Ann Campbell; Paulo J C Lin; Ying K Tam; Gregory D Sempowski; Michael Farzan; Hyeryun Choe; Kevin O Saunders; Barton F Haynes; Hanne Andersen; Laurence C Eisenlohr; Drew Weissman; Florian Krammer; Paul Bates; David Allman; Michela Locci; Norbert Pardi
Journal:  Immunity       Date:  2020-07-30       Impact factor: 43.474

10.  Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 responses.

Authors:  Aurélie Bouteau; Christopher Herbst; Zhen Qin; Sonia Ndeupen; Zachary Hutchins; Drishya Kurup; Leila Zabihi Diba; Botond Z Igyártó
Journal:  bioRxiv       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.